Zhaoke Ophthalmology-B: Beimei Prostaglandin Eye Drops (Jingbeiqing®) Approved by the National Medical Products Administration for Marketing

智通財經
2024.09.19 22:27
portai
I'm PortAI, I can summarize articles.

兆科眼科-B 宣佈，其研發的抗青光眼藥物貝美前列素滴眼液 (晶貝清®) 已獲得國家藥監局批准上市。這是中國首款不含防腐劑的單劑量貝美前列素滴眼液，旨在降低開角型青光眼及高眼壓症患者的眼壓，改善患者舒適感，並提高用藥依從性。

智通財經 APP 訊，兆科眼科-B(06622) 發佈公告，由公司研發生產的抗青光眼藥物貝美前列素滴眼液 (晶貝清®) 獲得國家藥品監督管理局 (國家藥監局) 批准上市。

貝美前列素滴眼液 (晶貝清®) 乃中國首款不含防腐劑的單劑量貝美前列素滴眼液，用於降低開角型青光眼及高眼壓症患者的眼壓。該款藥物不含防腐劑，避免青光眼患者因長期使用含有防腐劑的藥物而導致眼表受損。與此同時，該款藥物亦有助於改善患者於治療期間的舒適感，減少對防腐劑相關敏感的風險。其每日一次用藥頻率亦有助於提高患者依從性。

Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.